Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Liquid biopsy, Technology and innovation, Screening and monitoring, Genetics and epigenetics, Profession, Precision medicine, Omics, Oncology

A Win-Win Situation

In 2014, the clinical sequencing team and our pharmaceutical partners began a collaboration focused on increasing the use of next-generation sequencing (NGS) in the clinical domain. We saw an obvious unmet need, especially in oncology, and we believed that NGS could help patients find the right therapy faster. NGS includes tissue (solid tumor biopsy) sequencing, of course, but liquid biopsy has the potential to become the laboratory professionals’ assay of choice for several reasons: it’s less invasive than a typical solid tissue biopsy, hence potentially cheaper for patients and healthcare providers, and can be used when obtaining a solid tissue biopsy is not feasible due to location of tumor or patient health.

The liquid biopsy sample is usually blood, but it can be any fluid containing genetic material; the source of the DNA or RNA is irrelevant after sample preparation. Of course, nucleic acids – though currently the main focus of liquid biopsy studies – aren’t the end of the story; such tests have the ability to examine not only DNA and RNA, but also proteins, exosomes, and entire circulating tumor cells.

Read the full article now

Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Joydeep Goswami

Joydeep Goswami is President of Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific, Carlsbad, USA.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register